Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus

Table 5 Association between diabetes duration/treatment and International normalized ratio level n (%)

Variable	INR < 1.20 (n = 36)	INR≥1.20 (n = 27)	P value	INR < 1.50 (n = 52)	INR≥1.50 (n = 11)	P value
Duration of diabetes, yr
< 5	15 (41.70)	13 (48.10)	0.608	23 (44.20)	5 (45.50)	1.000
≥ 5	21 (58.30)	14 (51.90)	-	29 (55.80)	6 (54.50)	-
Age at diabetes diagnosis, yr
< 50	11 (30.60)	12 (44.40)	0.257	15 (28.80)	8 (72.70)	0.016
≥ 50	25 (69.40)	15 (55.60)	-	37 (71.20)	3 (27.30)	-
Diabetes treatment
Oral treatment
Non-users	21 (58.30)	19 (70.40)	0.326	31 (59.60)	9 (81.80)	0.296
Users	15 (41.70)	8 (29.60)	-	21 (40.40)	2 (18.20)	-
Insulin treatment
Non-users	27 (75.00)	25 (92.60)	0.138	43 (82.70)	9 (81.80)	1.000
Users	9 (25.00)	2 (7.40)	-	9 (17.30)	2 (18.20)	-
Diet only
Non-users	16 (44.40)	17 (63.00)	0.145	26 (50.00)	7 (63.60)	0.411
Users	20 (55.60)	10 (37.00)	-	26 (50.00)	4 (36.40)	-
Type of oral treatment
Biguanide
Non-users	32 (88.90)	22 (81.50)	0.640	43 (82.70)	11 (100)	0.310
Users	4 (11.10)	5 (18.50)	-	9 (17.30)	0 (0)	-
Sulfonylureas
Non-users	29 (80.60)	23 (85.20)	0.886	42 (80.80)	10 (90.9)	0.713
Users	7(19.40)	4 (14.80)	-	10 (19.20)	1 (9.1)	-
α-glucosidase inhibitor
Non-users	29 (80.60)	25 (92.60)	0.323	44 (84.60)	10 (90.9)	0.946
Users	7 (19.40)	2 (7.40)	-	8 (15.40)	1 (9.1)	-

INR: International normalized ratio.